You just read:

Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

News provided by

Regeneron Pharmaceuticals, Inc.

Jun 14, 2019, 07:00 ET